NASDAQ:KYTX Kyverna Therapeutics Q1 2026 Earnings Results & Report $5.68 -0.09 (-1.56%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$6.02 +0.34 (+5.97%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kyverna Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.66 versus the -$0.75 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call4:00 PM ET Kyverna Therapeutics EPS ResultsActual EPS-$0.66Consensus EPS -$0.75Beat/MissBeat by +$0.09One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersKyverna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsKyverna Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kyverna Therapeutics Q1 2026 Earnings FAQ Did Kyverna Therapeutics beat earnings estimates for Q1 2026? Kyverna Therapeutics (NASDAQ:KYTX) reported earnings of -$0.66 per share for Q1 2026, beating the consensus estimate of -$0.75. The report was announced on Tuesday, May 12, 2026. When is Kyverna Therapeutics' next earnings date? Kyverna Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Kyverna Therapeutics on the company's earnings history page. Kyverna Therapeutics Earnings HeadlinesKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026October 7, 2026 | globenewswire.comHEALTH ROUNDS-Appendix removal linked with lower colon cancer risk in studyOctober 2, 2026 | marketscreener.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD) and Kyverna Therapeutics, Inc. (KYTX)September 25, 2026 | theglobeandmail.comKYTX stock reverses gains after one-year cell therapy trial data but CEO says disease burden justifies a premium priceSeptember 25, 2026 | msn.comKYTX stock reverses gains after one-year cell therapy trial data — but CEO says disease burden justifies a premium priceSeptember 24, 2026 | msn.comSee More Kyverna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email. Email Address About Kyverna TherapeuticsKyverna Therapeutics (NASDAQ:KYTX) is a clinical-stage biotechnology company focused on developing cell therapies for severe autoimmune diseases. The company is working to apply chimeric antigen receptor T-cell (CAR T) technology, traditionally used in certain cancers, to conditions in which abnormal B cells contribute to disease. Kyverna’s lead product candidate, KYV-101, is an autologous, fully human CD19-directed CAR T-cell therapy designed to eliminate B cells and potentially reset dysfunctional immune responses. The company is evaluating KYV-101 in several autoimmune indications, including systemic lupus erythematosus, lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathies, multiple sclerosis and myasthenia gravis. Founded in 2018 and headquartered in Emeryville, California, Kyverna is advancing its therapies through clinical development and collaborations with academic and medical research centers. The company does not currently have an approved commercial product and is primarily focused on generating clinical evidence for its autoimmune cell therapy platform.View Kyverna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
